Clinical trials have grown more complex than ever before. Protocols are becoming more specialized, endpoints more refined, and eligibility criteria narrower and more precise. At the same time, development programs are expected to move faster and operate with greater efficiency. Despite this dual pressure, feasibility projections often rely on high-level estimates or investigator recall rather than validated assessments of patients who truly meet protocol criteria in a real-world clinical
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
ConcertAI Expands CancerLinQ Suite with AI-Driven Trial Matching
What You Should Know
Healthcare intelligence leader ConcertAI has unveiled major AI-driven enhancements to its CancerLinQ Suite at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.Powered by Cara, ConcertAI’s proprietary agentic AI platform, the suite automatically parses structured and unstructured data on a weekly basis across a massive footprint of 13 million patient records.The upgraded TriaLinQ module automates patient screening for complex biomarkers and lines of
Read More
Cypher AI Secures $2M to Scale AI-Native Infrastructure for Life Science R&D
What You Should Know
Life science infrastructure startup Cypher AI has emerged from stealth, announcing a $2M seed funding round led by MaC Venture Capital.The financing includes strategic participation from Epsilon Ventures, Connecticut Innovations, Sparta Group, and LiquidMetal Ventures.Founded in 2025 by former scientist and engineer Yaoyu Yang, PhD, the platform replaces fragmented spreadsheets, disconnected Electronic Lab Notebooks (ELNs), and legacy Laboratory Information Management
Read More
b.well Connected Health Partners with myTomorrows to Launch AI-Driven Clinical Trial Matching Stack
What You Should Know
Consumer health data platform b.well Connected Health has announced a strategic partnership with global health tech leader myTomorrows to automate and accelerate how patients are matched and enrolled into clinical trials.The collaboration combines b.well’s extensive, FHIR-based data network—which integrates longitudinal records from nearly 2.4 million providers, 330 health plans, and multiple state health information exchanges (HIEs)—with myTomorrows’ AI-powered clinical
Read More
Century Health Raises $5M for CHARM AI Platform to Accelerate Life Sciences Research
What You Should Know
Century Health has closed an oversubscribed $5M seed financing round led by Origin Ventures, bringing its total funding to an industry-accelerated position.The platform's proprietary Century Health Abstraction & Retrieval Model (CHARM) automates the curation of unstructured EHR data (notes, reports, and documentation), achieving a 97% accuracy rate validated against clinical expert judgment.Century Health expanded its specialty provider data network 60x over the past
Read More
Parexel Launches ParexelAI Suite of Human-Led AI Services for Clinical Trials
What You Should Know
Parexel has introduced ParexelAI™, a proprietary suite of human-led AI services designed to accelerate clinical development operations.Quantified Efficiencies: The suite is already delivering a 50% reduction in site selection timelines, a 30% reduction in medical writing for Clinical Study Reports, and a 20% reduction in safety literature screening.Regulatory Acceleration: Through a strategic partnership with Weave Bio, Parexel is reducing Investigational New Drug (IND)
Read More
Roche Acquires PathAI to Automate Cancer Diagnostics in $1B Deal
What You Should Know
Global healthcare leader Roche has entered into a definitive merger agreement to acquire US-based digital pathology pioneer PathAI for an upfront purchase price of $750M, with up to $300M in additional milestone payments.The acquisition marks the culmination of a deep strategic partnership first established between the two companies in 2021 and expanded in 2024 to co-develop AI-enabled companion diagnostic algorithms.PathAI’s flagship AISight Image Management System (IMS)
Read More
Axoft Secures $55M for Implantable Brain-Computer Interfaces and Fleuron™ Material Global Trials
What You Should Know
Axoft has raised an oversubscribed $55M Series A led by C.P. Group Innovation, bringing its total funding to over $60M.The capital will be used to expand global clinical trials, progress U.S. regulatory approval for its implantable Brain-Computer Interfaces (iBCIs), and build a GMP manufacturing facility in Cambridge, MA.Axoft’s iBCIs utilize a proprietary material called Fleuron™, which is 10,000x softer than traditional polyimide, significantly reducing tissue scarring
Read More
CareDx to Acquire Naveris for $160M to Expand into HPV-Driven Cancer MRD Monitoring
What You Should Know
CareDx has entered into a definitive agreement to acquire Naveris, a precision oncology company specializing in blood-based monitoring for viral-mediated cancers.The deal includes $160M in up-front cash, with potential for an additional $100M based on future revenue milestones.Naveris’ flagship platform utilizes Tumor Tissue Modified Viral (TTMV®) DNA to detect and monitor HPV-driven cancers with high accuracy.The acquisition is expected to close in the third quarter of
Read More
Weave Bio Launches AI-Native NDA Submission Support in Strategic Partnership with Parexel
What You Should Know
Weave Bio has expanded its AI-native regulatory platform to support New Drug Application (NDA) submissions, covering the full drug development lifecycle.Strategic partner Parexel co-developed and refined the platform, resulting in authoring speeds that are 60% faster than traditional manual methods.The platform utilizes AI-native data extraction, content verification, and automated authoring to synthesize clinical, non-clinical, and manufacturing data.Parexel will
Read More
